MRD-associated Non-intensive But Non-interruptive Treatment of Ph-negative Acute Lymphoblastic Leukemia Adult Patients

This study is evaluating a less intensive but continuous treatment approach for adults with a type of blood cancer called Ph-negative acute lymphoblastic leukemia (ALL). Researchers are tracking a measure called minimal residual disease (MRD) — tiny amounts of cancer cells remaining after treatment — to guide therapy decisions and avoid over-treatment. **You may be eligible if...** - You are between 18 and 55 years old - You have been newly diagnosed with Ph-negative ALL (a specific type of leukemia that does not have the Philadelphia chromosome) - You have not yet received treatment for this condition **You may NOT be eligible if...** - You are older than 55 - Your leukemia is Ph-positive (has the Philadelphia chromosome) - Your leukemia has already been treated or has come back after previous treatment Talk to your doctor to see if this trial is right for you.